摘要
目的探讨非小细胞肺癌(NSCLC)组织中雌激素受体α(ERα)的表达与表皮生长因子受体(EGFR)突变之间的关系。方法应用免疫组织化学法及实时荧光定量聚合酶链反应法检测286例NSCLC中ERα的表达及EGFR突变情况,并分析其与临床特性的关系。结果 ERα表达阳性率为36.0%(103/286),在女性患者中的表达要显著高于男性患者(P=0.004),肿瘤最大直径小于或等于3cm的患者显著高于肿瘤直径大于3cm的患者(P<0.01)。EGFR基因突变62例(21.7%),在女性、腺癌、肿瘤直径较小的患者显著增多,在ERα表达阳性患者中显著高于ERα阴性者(P=0.001)。结论 NSCLC中ERα的阳性表达与EGFR基因突变相关,可能与EGFR信号通路的交叉调控有关。
Objective To investigate expression of ERa(estrogen receptor alpha) and EGFR mutations in non-small cell lung cancer (NSCLC) and explore their correlation to clinicopathologic characteristics. Methods We evaluated 286 resected NSCLC specimens for ERa expression by immunohistochemistry. EGFR mutations were evaluated with TaqMan real time polymerase chain reaction (RT-PCR). The correlation with clinicopathologic characteristics was analyzed. Results The positive expression rate of ERa was 36.0% (103/286). The positive expression of ERa in women was significantly higher than that in men (P= 0. 004) and the different ERa expression was associated with tumor diameter (P〈0.01). 62 (21.7 %) patients were EGFR mutation positive. EGFR mutation status was significantly associated with gender (woman versus man, P〈0.01), pathological subtypes (squamous carcinoma versus adenocarcinoma,P〈0.01) and the tumor diameter (≤3 cm versus 〉3 cm,P〈0.01). The expression of ERa had significant positive association with EGFR mutation status (mutation rate was significantly higher in patients with positive ERa ex- pression than that of patients with negative ERa expression). Conclusion Expression of ERa is related with EGFR mutation status in NSCLC and may associate with the crosstalk in EGFR signaling pathways.
出处
《重庆医学》
CAS
北大核心
2015年第21期2881-2883,2886,共4页
Chongqing medicine
基金
国家自然科学基金资助项目(81172240)
关键词
癌
非小细胞肺
受体
表皮生长因子
受体
雌激素
carcinoma
non-small-cell lung
receptor, epidermal growth factor
receptor, estrogen